Open access · OA
via OpenAlex
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains
Matthew E. Gegg, Derek Burke, Simon Heales, Jonathan M. Cooper, John Hardy, Nicholas Wood, Anthony H.V. Schapira
Annals of Neurology · 2012 · ▲ 572 citations
Abstract
OBJECTIVE: Mutations in the glucocerebrosidase gene (GBA) represent a significant risk factor for developing Parkinson disease (PD). We investigated the enzymatic activity of glucocerebrosidase (GCase) in PD brains carrying heterozygote GBA mutations (PD+GBA) and sporadic PD brains. METHODS: GCase activity was measured using a fluorescent assay in cerebellum, frontal cortex, putamen, amygdala, and substantia nigra of PD+GBA (n = 9-14) and sporadic PD brains (n = 12-14). Protein expression of GCase and other lysosomal proteins was determined by western blotting. The relation between GCase, α-synuclein, and mitochondria function was also investigated in vitro. RESULTS: A significant decrease in GCase activity was observed in all PD+GBA brain areas except the frontal cortex. The greatest deficiency was in the substantia nigra (58% decrease; p < 0.01). GCase activity was also significantly decreased in the substantia nigra (33% decrease; p < 0.05) and cerebellum (24% decrease; p < 0.05) of sporadic PD brains. GCase protein expression was lower in PD+GBA and PD brains, whereas increased C/EBP homologous protein and binding immunoglobulin protein levels indicated that the unfolded protein response was activated. Elevated α-synuclein levels or PTEN-induced putative kinase 1 deficiency in cultured cells had a significant effect on GCase protein levels. INTERPRETATION: GCase deficiency in PD brains with GBA mutations is a combination of decreased catalytic activity and reduced protein levels. This is most pronounced in the substantia nigra. Biochemical changes involved in PD pathogenesis affect wild-type GCase protein expression in vitro, and these could be contributing factors to the GCase deficiency observed in sporadic PD brains.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/ana.23614
- Canonical
- link ↗
- Fetched
- 2026-06-03 MST
Cite this
APA
Gegg, M.E., Burke, D., Heales, S., Cooper, J.M., Hardy, J., Wood, N., & Schapira, A.H. (2012). Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. <em>Annals of Neurology</em>. https://doi.org/10.1002/ana.23614
Vancouver
Gegg ME, Burke D, Heales S, Cooper JM, Hardy J, Wood N, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Annals of Neurology. 2012. doi:10.1002/ana.23614.
BibTeX
@article{matthew2012Glucoc,
title = {Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains},
author = {Matthew E. Gegg and Derek Burke and Simon Heales and Jonathan M. Cooper and John Hardy and Nicholas Wood and Anthony H.V. Schapira},
journal = {Annals of Neurology},
year = {2012},
doi = {10.1002/ana.23614},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Nature Communications 2019
Open access · CC-BY
Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson’s disease pathogenesis
Frontiers in Neuroscience 2017
Open access · CC-BY
Mitochondrial Bioenergetics Is Altered in Fibroblasts from Patients with Sporadic Alzheimer's Disease
PLoS ONE 2012
Open access · CC-BY
Astrocyte Senescence as a Component of Alzheimer’s Disease
FEBS Journal 2009
Open access · OA
Human telomeric G‐quadruplex: The current status of telomeric G‐quadruplexes as therapeutic targets in human cancer
Journal of Alzheimer s Disease 2006
Citation only
Mitochondrial genomic contribution to mitochondrial dysfunction in Alzheimer's disease
Epigenomics 2016
Open access · CC-BY